Market Overview

Jefferies: Constellation Brands Is Our Top Large-Cap Growth Idea

Share:
Jefferies: Constellation Brands Is Our Top Large-Cap Growth Idea
Read more about our latest Cannabis News! CANNABIS HOME

Shares of alcohol beverage maker Constellation Brands, Inc. (NYSE: STZ) have lost 7 percent year-to-date and the steep discount versus its peers makes it Jefferies' top large-cap growth idea.

The Analyst

Kevin Grundy maintains a Buy rating on Constellation Brands with an unchanged $283 price target.

The Thesis

Constellation Brands is scheduled to report its second-quarter results Thursday morning, which Grundy said should come in ahead of expectations. The company likely benefited from favorable summer weather and product innovation. Third-party sales trends from Nielsen suggests a 13.5-percent growth in the beer business, which accounts for around 70 percent of total profit.

Constellation is expected to report Q2 earnings of $2.60 per share on sales of $2.25 billion.

Investors can expect to see a downward revision to management's $9.40 to $9.70 EPS guidance for the full year due to the $4 billion investment in Canopy Growth Corp (NYSE: CGC), Grundy said in a note. A reasonable guide down to a new range of $9.10-$9.40 is justified due to near-term dilution and any accretion from the deal isn't expected until fiscal 2021.

The stock's weakness since the start of the year implies shares are trading at 15 times NTM EV/EBITDA (excluding the Canopy portion of the business), which is a discount to the 17 to 18 times recent average and its peers who trade at around 21 to 22 times.

As such, the stock is a top large-cap growth idea based on expectations for continued growth in beer through at least 2021, exposure to the new cannabis market and an attractive valuation.

Price Action

Constellation Brands was trading flat Wednesday around $212.28 per share.

Related Links:

Constellation Brands Is Overvalued, Susquehanna Says In Downgrade

Stifel's 5-Year Bullish Stance On Constellation Brands Fizzles

Latest Ratings for STZ

DateFirmActionFromTo
May 2019DowngradesOverweightEqual-Weight
Apr 2019DowngradesBuyHold
Mar 2019Initiates Coverage OnOutperform

View More Analyst Ratings for STZ
View the Latest Analyst Ratings

Read more about our latest Cannabis News! CANNABIS HOME

Posted-In: alcohol BeerAnalyst Color Cannabis Previews Markets Analyst Ratings Trading Ideas Best of Benzinga

 

Related Articles (STZ + CGC)

View Comments and Join the Discussion!

FDA Approves Paratek's Bacterial Pneumonia, Skin Infection Treatment

It Might Finally Be Time For Emerging Markets ETFs